Key facts
- NuVision Biotherapies’s last known valuation is $13.0M (Feb 2026).
- It has raised $13.4M; the latest was Later Stage VC ($6.5M) in Feb 2026.
- Notable investors include Innovate UK, Mercia Ventures, European Regional Development Fund (Brandenburg), Midlands Engine Investment Fund, Maven Cognition — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for NuVision Biotherapies
- ·The full record, as it builds
Funding rounds
No funding rounds for NuVision Biotherapies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NuVision Biotherapies
Developer of ophthalmic therapy products designed to offer ophthalmic surgeons innovative new therapies for ocular care. The company's therapy harnesses the regenerative properties of amniotic tissue to improve recovery from front-of-the-eye disease, surgical and other traumatic injuries, enabling patients to get quality and affordable biotherapies for treating the front-of-the-eye disease and trauma.
- Sector
- Healthcare
- HQ
- Nottingham, United Kingdom
- Founded
- 2015
- Employees
- 24
- Website
- nu-vision.co.uk/
- Ownership
- Privately Held (backing)
NuVision Biotherapies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NuVision Biotherapies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NuVision Biotherapies in its N-PORT filings yet. We sweep new filings monthly.